Our HIV research at the AIDS 2026 Conference in Brazil
21 Jul 2026
Researchers from the Innovative Clinical Trials Unit (InCTU), alongside international partners, will present their latest findings on HIV trials at the 26th International AIDS Conference on HIV Science. The conference will take place in Rio de Janeiro, Brazil, and virtually on 26-31 July 2026.
Our HIV trials, including D3 and LATA, will be featured in both oral presentations and poster sessions at the main AIDS conference, as well as at the 18th International Workshop on Paediatrics & HIV 2026, a pre-conference event taking place on Friday 24 and Saturday 25 July.
The AIDS Conference is one of the most influential global forums for HIV research, bringing together scientists, policymakers, and advocates to share advances in clinical, basic, and operational HIV science.
A full list of InCTU presentations at both the main conference and pre-conference workshops is available below.
AIDS 2026 Conference
|
Date and time (BRT) |
Session |
Title |
Presenter |
|
Wednesday 29 July, 10:30-11:30 AM |
AIDS 2026: Co-Chairs' Choice |
LATA 96-week results |
Dr Mutsa Bwakura Dangarembizi |
|
Thursday 30 July, 10:30-11:30 AM |
Ageing with HIV: Live long, live strong
|
The impact of archived HIV-1 drug resistance on maintenance of virologic suppression through Week 48 in children aged 2 to <15 years receiving DTG/3TC: PENTA-21 intensive pharmacokinetic sub-study |
|
International Workshop on Pediatrics & HIV 2026
|
Date and time (BRT) |
Session |
Title |
Presenter |
|
24 July 2026 |
Session 4: Pediatric and Adolescent Care and Treatment Oral Abstract Presentations 2
|
Predictors of viral non-suppression in children living with HIV initiating second-line antiretroviral therapy in the ODYSSEY and CHAPAS-4 trials
|
Pauline Amug |
|
24-25 July 2026 |
Poster |
HIV-1 resistance in children aged 2 to <15 years receiving DTG/3TC or DTG+2NRTI: results from the D3/PENTA-21 trial over 96 weeks. |
Johannes C Botha |
|
25 July 2026, 4.15-5.15 PM |
Poster (92) |
Prevalence of renal impairment in children and young adults living with HIV in Europe and Thailand |
John O’Rourke |
|
24-25 July 2026 |
Poster |
T-Cell Subsets, T-Cell Receptor Repertoire and HIV-1 Virological Reservoir in Children Initiating First-Line Dolutegravir versus Standard-Of-Care ART: Results from the ODYSSEY Trial |
Matt Byott (on behalf of Kathleen Gartner) |
Further information: